{"name":"A2 Biotherapeutics Inc.","slug":"a2-biotherapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"A2B694","genericName":"A2B694","slug":"a2b694","indication":"Other","status":"phase_1"},{"name":"A2B395","genericName":"A2B395","slug":"a2b395","indication":"Other","status":"phase_1"},{"name":"A2B530","genericName":"A2B530","slug":"a2b530","indication":"Other","status":"phase_1"},{"name":"A2B543","genericName":"A2B543","slug":"a2b543","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"A2B694","genericName":"A2B694","slug":"a2b694","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"A2B395","genericName":"A2B395","slug":"a2b395","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"A2B530","genericName":"A2B530","slug":"a2b530","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"A2B543","genericName":"A2B543","slug":"a2b543","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxPQ1paZGRoQXk2RGhYbFExZmt1NXhaeENkUmpzT0dndFdYTWJhaVdMblpjRVRnN0JtRVZrSXpsVk4yQ1Z5SWhycjBPRHBRaThFZFY3MXA2VkJIU3hQZXBrd0FBcGptZzhkN3JNS2ZuUncwZUlPaFh1cnVwUTJPNFdQNEtoZy1CVDI3RmZMUzAtWW5iYWhnZVlXaDFURlFfc1RxandxUHlWMGdQMnlhT3NDODFwaE1oX19yZC1QalNjZTBaSGt3Q2xWNEJlSUU0R09tTHFwVXhYdHNDUEVqV2o1SkhGUS1yLTZuV2ViRjRjVkpzV0lHOUNiZXAyQUVvVE5yY0N4UlFsM28yTWNTcW9Yc01wV0hkdjNMbVNnTUFtdVRJNUEtTHpqc1NDMFg0UEhxa1E?oc=5","date":"2026-04-01","type":"regulatory","source":"Business Wire","summary":"A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster - Business Wire","headline":"A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxPVUhxUU14SEZ5eHFyRTBxNkdwV1BNR19mYmVmbnZnSzNaanNJQ085RUpqWTBuaGZkOGtjM3ZVZE5BSVNLa09WWVM3MkF1ZWFlakM0N29nVVp6TTJGelZYMWN3VE9sSDVFbWp3TXI5T1Jvc1gwdzExVl9jckFfdlk2bVdaTEJBQ2dFR0UybHZtUjFXcGVqR3FGNDVHWDdibG94cDU4bk9EQWsyUGJOUVhGTncwTi02eFBwajN6aHZBTFA2cU5saWxBUkNucUdVQlJTTW1Eanl3OFhxOTFlb21aeHpmTUlnbmFOQndZcnpIWmVRejNfanhjakRkQVNtVUZXQ3ZOT1R3WlJQMm1oLW9LR3VLTXdFZlMyUTc3RTllMm1lN3pWUHV2Nk9WMXVFdTls?oc=5","date":"2026-02-26","type":"trial","source":"Business Wire","summary":"A2 Biotherapeutics Doses First Patient in EVEREST-2 Study with A2B543, a Logic-Gated CAR T Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster - Business Wire","headline":"A2 Biotherapeutics Doses First Patient in EVEREST-2 Study with A2B543, a Logic-Gated CAR T Cell Therapy Enhanced with a ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNWkZJbTFkU0xpSzFyRzdLbnJVOXliSjlMdVNvTkxQcHZFdWtYb3NnQW5IajRGeVd6UVJzYTBLdkJMQlBKQURNSEtVYWttNXRHSGlXZnVnTXpxU09uTkhJUXRPa2FlWXgzcWZKdEdsV2ZjcHlqenRTUXNsWE8ydzlHR0llRkJvRnM2ZF9LbElDSjBoWEJtb2pIeUtEZkpLOVJuaVZGT3lRUWlIejBISWRYU0dnTFE4QnBVZXhhSUFQQ3A2RS1qT2tfMmxTQQ?oc=5","date":"2026-01-26","type":"pipeline","source":"Business Wire","summary":"Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire","headline":"Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPQ0JCT3d3STRGaFQ2LUdMMnNLRVVLbjNVTDQwTTV3RENtNUZVVnZmMWNEODVSSmF6eEVGNnNRUXRhWHRJc3pCVU9oZFlFR3Q4T2hvNWVKdWpOUFc2Vy0tdjlFbGNQR0FUUUhmYTNnVmpMLWYwZ3lhOElEempjTEp3QzZnc19Na2tGd3BZZ2xhVGwxSjJNRzFKQXlGeEZnVEF0V1Z2NGdxRUFHOEVq?oc=5","date":"2026-01-26","type":"pipeline","source":"Contract Pharma","summary":"Janux Therapeutics Taps Dr. William Go as Chief Medical Officer - Contract Pharma","headline":"Janux Therapeutics Taps Dr. William Go as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-09","type":"regulatory","source":"BioSpace","summary":"A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express Mesothelin and Have Lost HLA","headline":"A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locall","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOQkxmbk12TjRSRXhEVnFZTGotcy1sUlZsYXdPSTNBeV9BTk40QnJraDBzeHppNGpuR0JLVmk3TV82a0drdXhTdUpGOTgzMk5DbVdlclZYMTQzSzlfelE1eTdwYXpGVXBNMzV6eW05ZjBPLTFTMHF5TUNscEVlTkhqWQ?oc=5","date":"2025-12-19","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPN2Q4bUd5RWFzeTV1ZXdXRHo2aVBqd3RoRFRBeF91MUR2aWNNdWRTbkwwZ3d1cFdka0JzWTNGS01NQ3RXZVAtaG9WRnV4QnFDQWswRTdrZENyQVdXSTJxWS1EZ0tDWVVyLXhaRklQeHhUQmpsbTZaNUlCNzgteWxuSXNVZmJlMW1MRkRsODlFNFdBNDluUDZJdDZtdUZjblNzcDk2RHJxR29xZw?oc=5","date":"2025-11-04","type":"pipeline","source":"BioSpace","summary":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces - BioSpace","headline":"BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNUS1FajhEMWEyWURmbExFOHY5b05pS2pYUktnaVo4V0ZZWHV3NUtKRm1XVDg3cm5VcTdfRkJObFJQeUx3dFdiSk1PQWJYVlYwWjNTSktVM3FCOHIwR3JFTnJUUWV2UGhzUlVKSjZKSzlPZHFLTWh2NzdQaU40d3dFb3o3bWpwdk0zNFY5OEREVkJuN3k1akRnTl9iX29Iei0yTXdSZWZ0REJUXzhJdklmLVNhRUhhMUhJZVFjdlNqdWk4VU54UkR4endtdjJCQmQyajhGTnRqRV9YVTY4TUFacDF6U1B5ZjVMX2VocXJUekZfODRaUWxkZUV3ZEtUUHEyTHJUSzNTelU3Ujg?oc=5","date":"2025-10-05","type":"trial","source":"BioSpace","summary":"A2 Bio to Present Early Safety and Efficacy Data from EVEREST-2 Study during 2025 Annual Meeting of the Society for Immunotherapy of Cancer - BioSpace","headline":"A2 Bio to Present Early Safety and Efficacy Data from EVEREST-2 Study during 2025 Annual Meeting of the Society for Immu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBlYy1ab3RTQ2FuSlItUF9GYW5sRi0xUVZjczlLZjVJTmVzenNpdnRLVGpBWXZianVfenFWckMzNUVGbUhQUlNrVEplNTVzelNwMm81ZHJjX1pNVDZ0U0pKelp5eHpoUVNIc01jU3JsdC1XOWxpdE82OA?oc=5","date":"2025-05-18","type":"pipeline","source":"Los Angeles Times","summary":"Top Life Science Companies - Los Angeles Times","headline":"Top Life Science Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPR2lOZVhmVWltLV96Z0xueEx3UXZTMjJZalRDZzBzOVlQcDNOUVkwVnZVT0FPVFdCMHJUMnRMNzNSb2dlTUd2b0Z0S3JkQXdEZmdEWWlIR1pmcXVjbTJ0bGdfMFhydElZQjRQcGZjUTJtQmJMX0hONU5qQTVDOFBmdW5CY0ZWS3R0Y3RIWGEtaHVGbkFQaW1DTlVOMU1RYlk2N1VZbExDMTBJRERyX0JaODJxY3dZbTFDUVc3T0x3?oc=5","date":"2025-05-06","type":"pipeline","source":"prnewswire.com","summary":"ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc. - prnewswire.com","headline":"ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBjMHNzU3NrWS12RUlHbC1nUHczN3dDdDVuS2ZacWlWbmdGOXZpTGtwRlpfYnBPMnBNQ1RQaER4Y283TnNJUkotMTRiWXc4SEJiTDBfN3NYaF9VWWw5QVNXLW04UlltZHU4Wmk4WDUyM2M5dkxhMDRvVHh3?oc=5","date":"2024-06-13","type":"pipeline","source":"Labiotech.eu","summary":"Eight companies tackling cancer with allogeneic cell therapy in 2024 - Labiotech.eu","headline":"Eight companies tackling cancer with allogeneic cell therapy in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQRmd4MEdJZ0swMlgyc0dObTNic2ZGZ2tyR1lmbTZLNk5JTGRONEZHaVBiamM2SnVWSHVJbF9peU94YVZtRzlMR3NLNzhLakNaS2V3NF8ybV9WNjZNRVNWM1JaX1BwdmVYR1hVRG5RM2VYODZxLU1iZ0xTZVZSbTl6RHIta2c?oc=5","date":"2022-08-29","type":"pipeline","source":"Los Angeles Business Journal","summary":"A2 Bio’s HQ Move - Los Angeles Business Journal","headline":"A2 Bio’s HQ Move","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}